AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

Next year’s flu season will have an additional option for people looking to protect themselves: a flu vaccine that can be ...

Next year’s flu season will have an additional option for people looking to protect themselves: a flu vaccine that can be ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

About Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies ...

This summary provides key updates in the health sector, including AstraZeneca's unsuccessful breast cancer trial, bird flu ...

Insurance companies could be required to cover asthma inhalers at no cost in New York state. Assemblywoman Jessica ...

Insurance companies could be required to cover asthma inhalers at no cost in New York state. Assemblywoman Jessica ...

The companies now plan on starting this year another large study of their drug, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators.

Johnson & Johnson's stock has seen modest gains in recent months. Read why I downgrade JNJ stock from buy to hold.

Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...

This summary covers various health news briefs including AstraZeneca's breast cancer drug trial results, a bird flu case in ...